February 24, 2015
Taiho Pharmaceutical announced on February 23 that the US FDA has accepted a new drug application (NDA) for its fixed-dose combination tablet containing trifluridine and tipiracil (brand name in Japan: Lonsurf) for the treatment of refractory metastatic colorectal cancer (mCRC)...read more